Is Your Patient Having Myeloma Instead? Expert guidance on avoiding misdiagnosis in your clinic

Abstract

Myeloma remains to this day a cancer that is diagnosed late.

Often without warning, diagnosis occurs only at the onset of irreversible late disease features like multiple bone fractures and renal damage, severely reducing patient outcomes.

Yet myeloma patients may remain asymptomatic or first present to non-hematology clinics with unspecific symptoms confused with other diseases.

To improve disease identification and minimize misdiagnosis risk, it is most crucial for all medical practitioners and specialties to understand clinical features of myeloma and early diagnostic approaches.

In this webinar, leading hematology expert and International Myeloma Foundation’s Brian G.M. Durie Outstanding Achievement Awardee, Professor Wee Joo Chng will share his impactful clinical experience towards identifying myeloma in your medical practice

Speaker's biography

Professor Wee Joo is a member of many international professional committees, such as American Society of Haematology Scientific Committee on Plasma Cell Neoplasia, the International Myeloma Working Group and the Asian Myeloma Network. He is also involved in a number of Grant Review Committees, Conference Organising Committee, Advisory Boards and Steering Committees of Global Clinical Trials. He has authored more than 200 publications in many reputed journals, and actively participates in clinical trials and has delivered talks in many national and international conferences. He has won multiple awards for his research both locally and internationally including the National Medical Excellence Outstanding Clinician Scientist Award, the National Medical Research Council Senior Translational Research (STaR) Award, the National University of Singapore Young Researcher Award, and the Celgene Future Leaders in Haematology Award.

Professor Chng's current research is very translational and involves the use of high-resolution global genomic technique to understand biology, identify drug targets, understand drug resistance and improve disease prognosis in haematological malignancies, with the ultimate aim of improving patient’s outcome and personalizing treatment.